Related references
Note: Only part of the references are listed.Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats
Sukyung Woo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia
Qing Fan et al.
EXPERIMENTAL HEMATOLOGY (2006)
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers
Richard B. Stead et al.
BLOOD (2006)
Population cell life span models for effects of drugs following indirect mechanisms of action
JJ Perez-Ruixo et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin
K Jolling et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers
R Ramakrishnan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Population plharmacokinetic analysis of pegylated human erythropoietin in rats
K Jolling et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
JW Eschbach et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Development and characterization of novel erythropoiesis stimulating protein (NESP)
JC Egrie et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
